Ngā hua rapu kaituhi

1

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer mā Konstantinopoulos, Panagiotis A., Matulonis, Ursula A.

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
2

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies mā Lee, Elizabeth K., Matulonis, Ursula A.

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
3

Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer mā Porter, Rebecca L., Matulonis, Ursula A.

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
4

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure mā Lee, Elizabeth K., Lindeman, Neal I., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
5

Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer mā Wang, Tianyi, Townsend, Mary K., Simmons, Vani, Terry, Kathryn L., Matulonis, Ursula A., Tworoger, Shelley S.

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
6

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor mā Robinson, Emily S., Matulonis, Ursula A., Ivy, Percy, Berlin, Suzanne T., Tyburski, Karin, Penson, Richard T., Humphreys, Benjamin D.

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
7

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma mā Stover, Elizabeth H., Feltmate, Colleen, Berkowitz, Ross S., Lindeman, Neal I., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
8

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers mā Przybytkowski, Ewa, Davis, Thomas, Hosny, Abdelrahman, Eismann, Julia, Matulonis, Ursula A., Wulf, Gerburg M., Nabavi, Sheida

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
9

Ovarian cancer mā Matulonis, Ursula A., Sood, Anil K., Fallowfield, Lesley, Howitt, Brooke E., Sehouli, Jalid, Karlan, Beth Y.

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
10

Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health mā Wright, Alexi A., Keating, Nancy L., Balboni, Tracy A., Matulonis, Ursula A., Block, Susan D., Prigerson, Holly G.

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
11

$Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type$

Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type mā Lee, Elizabeth K., Esselen, Katharine M., Kolin, David L., Lee, Larissa J., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
12

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks mā Yu, Kun-Hsing, Hu, Vincent, Wang, Feiran, Matulonis, Ursula A., Mutter, George L., Golden, Jeffrey A., Kohane, Isaac S.

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
13

Pre- and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a prospective cohort study mā Merritt, Melissa A., Rice, Megan S., Barnard, Mollie E., Hankinson, Susan E., Matulonis, Ursula A., Poole, Elizabeth M., Tworoger, Shelley S.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
14

High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary mā Matulonis, Ursula A., Hirsch, Michelle, Palescandolo, Emanuele, Kim, Eejung, Liu, Joyce, van Hummelen, Paul, MacConaill, Laura, Drapkin, Ronny, Hahn, William C.

I whakaputaina 2011

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
15

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells mā Choi, Young Eun, Battelli, Chiara, Watson, Jacqueline, Liu, Joyce, Curtis, Jennifer, Morse, Alexander N., Matulonis, Ursula A., Chowdhury, Dipanjan, Konstantinopoulos, Panagiotis A.

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
16

A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance mā Ceccaldi, Raphael, O'Connor, Kevin W., Mouw, Kent W., Li, Adam Y., Matulonis, Ursula A., D'Andrea, Alan D., Konstantinopoulos, Panagiotis A.

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
17

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer mā Gulhan, Doga C., Garcia, Elizabeth, Lee, Elizabeth K., Lindemann, Neal I., Liu, Joyce F., Matulonis, Ursula A., Park, Peter J., Konstantinopoulos, Panagiotis A.

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
18

Influence of Patients’ Preferences and Treatment Site on Cancer Patients’ End-of-Life Care mā Wright, Alexi A., Mack, Jennifer W., Kritek, Patricia A., Balboni, Tracy A., Massaro, Anthony F., Matulonis, Ursula A., Block, Susan D., Prigerson, Holly G.

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
19

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer mā Lee, Elizabeth K., Tan-Wasielewski, Zhenying, Matulonis, Ursula A., Birrer, Michael J., Wright, Alexi A., Horowitz, Neil, Konstantinopoulos, Panagiotis A., Curtis, Jennifer, Liu, Joyce F.

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
20

CA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations mā Cramer, Daniel W., O’Rourke, Dennis J., Vitonis, Allison F., Matulonis, Ursula A., DiJohnson, Daniel A., Sluss, Patrick M., Crum, Christopher P., Liu, Brian C.-S.

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Matulonis, Ursula A

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer mā Konstantinopoulos, Panagiotis A., Matulonis, Ursula A.

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies mā Lee, Elizabeth K., Matulonis, Ursula A.

Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer mā Porter, Rebecca L., Matulonis, Ursula A.

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure mā Lee, Elizabeth K., Lindeman, Neal I., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer mā Wang, Tianyi, Townsend, Mary K., Simmons, Vani, Terry, Kathryn L., Matulonis, Ursula A., Tworoger, Shelley S.

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor mā Robinson, Emily S., Matulonis, Ursula A., Ivy, Percy, Berlin, Suzanne T., Tyburski, Karin, Penson, Richard T., Humphreys, Benjamin D.

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma mā Stover, Elizabeth H., Feltmate, Colleen, Berkowitz, Ross S., Lindeman, Neal I., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers mā Przybytkowski, Ewa, Davis, Thomas, Hosny, Abdelrahman, Eismann, Julia, Matulonis, Ursula A., Wulf, Gerburg M., Nabavi, Sheida

Ovarian cancer mā Matulonis, Ursula A., Sood, Anil K., Fallowfield, Lesley, Howitt, Brooke E., Sehouli, Jalid, Karlan, Beth Y.

Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health mā Wright, Alexi A., Keating, Nancy L., Balboni, Tracy A., Matulonis, Ursula A., Block, Susan D., Prigerson, Holly G.

Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type mā Lee, Elizabeth K., Esselen, Katharine M., Kolin, David L., Lee, Larissa J., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks mā Yu, Kun-Hsing, Hu, Vincent, Wang, Feiran, Matulonis, Ursula A., Mutter, George L., Golden, Jeffrey A., Kohane, Isaac S.

Pre- and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a prospective cohort study mā Merritt, Melissa A., Rice, Megan S., Barnard, Mollie E., Hankinson, Susan E., Matulonis, Ursula A., Poole, Elizabeth M., Tworoger, Shelley S.

High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary mā Matulonis, Ursula A., Hirsch, Michelle, Palescandolo, Emanuele, Kim, Eejung, Liu, Joyce, van Hummelen, Paul, MacConaill, Laura, Drapkin, Ronny, Hahn, William C.

A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance mā Ceccaldi, Raphael, O'Connor, Kevin W., Mouw, Kent W., Li, Adam Y., Matulonis, Ursula A., D'Andrea, Alan D., Konstantinopoulos, Panagiotis A.

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer mā Gulhan, Doga C., Garcia, Elizabeth, Lee, Elizabeth K., Lindemann, Neal I., Liu, Joyce F., Matulonis, Ursula A., Park, Peter J., Konstantinopoulos, Panagiotis A.

Influence of Patients’ Preferences and Treatment Site on Cancer Patients’ End-of-Life Care mā Wright, Alexi A., Mack, Jennifer W., Kritek, Patricia A., Balboni, Tracy A., Massaro, Anthony F., Matulonis, Ursula A., Block, Susan D., Prigerson, Holly G.

CA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations mā Cramer, Daniel W., O’Rourke, Dennis J., Vitonis, Allison F., Matulonis, Ursula A., DiJohnson, Daniel A., Sluss, Patrick M., Crum, Christopher P., Liu, Brian C.-S.

Ngā utauta rapu: